Actelion sees Uptravi price of $160,000-170,000/patient

ZURICH (Reuters) - Swiss drug company Actelion expects an average annual per-patient price for its new pulmonary arterial hypertension medicine in the United States of $160,000 to $170,000, before rebates, Chief Operating Officer Otto Schwarz told analysts on Tuesday.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro